Semaglutide resolves MASLD inflammation

A meta-analysis of 10 randomised controlled trials covering 1,908 patients found that semaglutide resolved steatohepatitis in significantly more patients than placebo (OR 3.48, 95% CI 2.68-4.53) and reduced liver fat by 30% or more (OR 7.16, 95% CI 3.08-16.64), but did not produce a statistically significant improvement in fibrosis staging^[1]. Published in the British Journal of Clinical Pharmacology on 11 June 2026, the review offers the most current pooled look at where the evidence stands for semaglutide in metabolic dysfunction-associated steatotic liver disease (MASLD).

What the meta-analysis measured

Peng and colleagues searched databases through January 2026 and included 10 studies comparing semaglutide to a control group in patients with MASLD or the older diagnostic label NAFLD. The primary outcomes were histological resolution of steatohepatitis and improvement of at least one stage in liver fibrosis. Secondary outcomes included liver stiffness (measured by elastography), serum ALT and AST, liver fat content, and adverse events^[1].

The review was registered on PROSPERO (CRD420261288562) and followed PRISMA reporting guidelines, which require authors to document their search strategy, inclusion criteria, and risk-of-bias assessment in a standardised way^[1].

Key findings

For steatohepatitis resolution, the pooled odds ratio was 3.48 (p < 0.00001), meaning patients receiving semaglutide were roughly three and a half times more likely to see their liver inflammation resolve than those on placebo. Patients were also about seven times more likely to achieve a 30% or greater reduction in liver fat (OR 7.16, p < 0.00001)^[1].

Liver stiffness, a non-invasive proxy for fibrosis, fell by a mean of 1.25 kPa more in the semaglutide group than in controls (p = 0.009). However, histological fibrosis improvement of at least one stage was not statistically significant (OR 1.17, p = 0.72)^[1]. The authors noted that anti-fibrotic effects appear to depend on disease stage and treatment duration, with meaningful histological reversal observed mainly in non-cirrhotic patients over longer follow-up periods.

Gastrointestinal side effects (nausea, diarrhoea, constipation) were more common with semaglutide (RR 1.83, 95% CI 1.20-2.79), consistent with the known side-effect profile of GLP-1 receptor agonists. Serious adverse events did not differ significantly between groups (RR 1.07, 95% CI 0.82-1.39)^[1].

How this fits the broader evidence

These pooled results align with the Phase 3 ESSENCE trial, the largest single study of semaglutide for MASH (the inflammatory subtype of MASLD). In the ESSENCE interim analysis at 72 weeks, 62.9% of patients on 2.4 mg weekly semaglutide achieved steatohepatitis resolution without fibrosis worsening, compared with 34.1% on placebo. Fibrosis improvement of at least one stage reached 37.0% versus 22.5%^[2]. Mean weight loss in the semaglutide arm was 10.5 kg.

The FDA granted accelerated approval for semaglutide (marketed as Wegovy) in August 2025 for treating MASH with moderate-to-advanced fibrosis (stages F2-F3). In November 2025, the American Association for the Study of Liver Diseases (AASLD) updated its practice guidance to include semaglutide as a treatment option for this population, recommending non-invasive testing rather than biopsy for patient selection^[3].

A separate earlier trial in patients with established cirrhosis (NASH with F4 fibrosis) did not show benefit, suggesting that semaglutide works best before the disease reaches its most advanced stage^[4]. This stage-dependent pattern is consistent with the meta-analysis finding that fibrosis reversal was not statistically significant across the pooled studies, which included patients at various disease stages.

What this does not tell us

The meta-analysis pooled studies with different semaglutide doses, treatment durations, and patient populations, which may obscure dose-response relationships. Most included trials ran for 72 weeks or less, so longer-term effects on fibrosis progression, cirrhosis prevention, and liver-related clinical events remain unknown.

The mechanism by which semaglutide improves liver histology is not fully established. GLP-1 receptors are only sparsely expressed on hepatocytes, so the benefits may be largely indirect, driven by weight loss, reduced insulin resistance, and lower de novo lipogenesis rather than a direct hepatoprotective effect. Whether the liver benefits persist if patients regain weight after stopping treatment is an open question.

Semaglutide is approved for MASH with F2-F3 fibrosis, type-2 diabetes, and chronic weight management. It is not approved for all forms of MASLD, and the meta-analysis should not be read as evidence that everyone with fatty liver disease needs treatment. MASLD exists on a spectrum, and many patients with simple steatosis (fat accumulation without inflammation) may be better served by lifestyle changes alone. If you have been diagnosed with MASLD or MASH, talk to your doctor about whether pharmacotherapy is appropriate for your specific situation.